By Fineline Cube 
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.
Drug Innovation
GPN00884 eye drops represent a novel mechanism for delaying pediatric myopia progression. Unlike low-concentration atropine eye drops, GPN00884 does not cause pupil dilation or associated side effects such as photophobia and decreased accommodation. Its flexible dosing schedule enhances patient compliance.
Market Need
Currently, there is a significant unmet clinical need in China for effective and safe treatments to delay myopia progression in children, a gap that GPN00884 aims to address.-Fineline Info & Tech